Praziquantel, a new drug, has been registered
Mir-Pharm announces the successful registration of a new antihelminthic drug for the treatment of infections.
Moscow, June 2023
Praziquantel is indicated for use by adults and children over 4 years for the treatment of helminth infections (trematode infections) caused by:
● various species of schistosomes (Schistosoma haematobium, S. mansoni, S. intercalatum, S. japonicum, S. mekongi);
● liver fluke (Clonorchis sinensis, Opistorchis viverrini);
● pulmonary bipeds (Paragonimus westermani, other species).
The drug contains the active ingredient praziquantel, which quickly increases the permeability of helminth cell membranes for calcium ions, which in turn leads to a generalized contraction of Schistosoma muscles, turning into persistent paralysis and leading to their death. The drug causes vacuolization and subsequent damage to the epithelium of parasites, which makes them vulnerable to the host's immune system and its digestive enzymes. It also causes damage to the tegument (the outer covering of flatworms). It inhibits the uptake of glucose by helminth cells, while reducing the content of glycogen and stimulating the release of lactic acid compounds. As a result, the parasites die. Praziquantel belongs to the pharmacotherapeutic group “anthelmintic agent; means for the treatment of trematodoses; quinoline derivatives and related compounds.
Each film-coated tablet contains 600 mg of praziquantel. Other ingredients (auxiliaries) are: sodium carboxymethyl starch, microcrystalline cellulose (type 102), crospovidone, povidone, sodium lauryl sulfate, magnesium stearate, shell (hypromellose, macrogol 6000, titanium dioxide (E171)).
Note:
The press release contains information about prescription medications. Use of this information for preparation of publications must be made in accordance with the legislation of the Russian Federation on advertising (including but not limited to Art. 24 of the Federal Law of 13.03.2006 No. 38-FL "On Advertising"), according to which, in particular, advertising of prescription drugs is allowed only in places of medical or pharmaceutical exhibitions, workshops, conferences and other similar events as well as in specialized print media intended for medical and pharmaceutical workers. Failure to comply with the above requirements (namely, mentioning the name of the drug, placing an image of the package or its elements in the media other than specialized print publications intended for medical and pharmaceutical workers) shall entail administrative liability.